

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	Divisional of 09/603,713
		Filing Date	April 30, 2001
		First Named Inventor	Gerald Koelsch
		Group Art Unit	1653
		Examiner Name	Amal Mohamed
Sheet 1 of 11	Attorney Docket Number	OMRF 182 DIV	

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	US Patent Document		Name of Patentee or Applicant of Cited Document	Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
		5,200,339		Abraham	04-06-1993	
		5,733,768		Dixon et al.	03-31-1998	
		5,942,400		Anderson et al.	08-24-1999	
		5,978,740		Armistead	11-02-1999	
		5,986,054		St. George-Hyslop et al	11-16-1999	
		6,077,682		Inouye et al.	06-20-2000	
AM		*6,207,710		Audia et al.	03-27-2001	Class / subclass C14 / 551

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office. ³	Number ⁴	Kind Code ⁵ (if known)				
		EP	0 855 444	A2	SmithKline Beecham Pharmaceuticals	07-29-1998		
		JP	10 108 681	A	SmithKline Beecham Corp	04-28-1998		
		WO	96/40885	A2	Athena Neurosciences, Inc.	12-19-1996		
		WO	97/27296	A1	HSC Research and Development Limited Partnership; The Governing Council of the University of Toronto	07-31-1997		
		WO	98/13488	A2	Schering Aktiengesellschaft	04-02-1998		
		WO	98/15828	A1	Scios, Inc.	04-16-1998		
		WO	98/21589	A1	The Trustees of the University of Pennsylvania	05-22-1998		
		WO	98/26059	A1	Athena Neurosciences, Inc.	05-18-1998		
		WO	99/51752	A1	Chugai Seiyaku Kabushiki Kaisha	10-14-1999		

Examine Signature	Abdel A. Mohamed	Date Considered	8/5/03
-------------------	------------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commissioner for Patent, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-98)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<p>Substitute for form 1449A/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>(use as many sheets as necessary)</p>		Complete if Known	
		Application Number	Divisional of 09/603,713
		Filing Date	April 30, 2001
		First Named Inventor	Gerald Koelsch
		Group Art Unit	1613
		Examiner Name	
Sheet 2 of 11	Attorney Docket Number	OMRF 182 DIV	

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	US Patent Document		Name of Patentee or Applicant of Cited Document	Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office. ³	Number ⁴	Kind Code ⁵ (if known)				
		WO	99/64587 A1		Rhon-Poulenc Rorer	12-16-1999		
		WO	00/17369 A3		Pharmacia & Upjohn Co.	03-30-2000		
		WO	00/23576 A3		Vivian Hook	04-27-2000		
		WO	00/47618 A2		Elan Pharmaceuticals, Inc.	08-17-2000		
		WO	00/58479 A1		Amgen, Inc.	10-05-2000		
		WO	00/77030 A1		Elan Pharmaceuticals, Inc.	12-21-2000		
		*WO	01/23533 A2		Pharmacia and Upjohn Co.	04-05-2001		

Examine Signature	Abdel A. Mohamed	Date Considered	8/5/03
-------------------	------------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

+



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	Divisional of 09/603,713
		Filing Date	April 30, 2001
		First Named Inventor	Gerald Koelsch
		Group Art Unit	1653
		Examiner Name	
Sheet 3 of 11	Attorney Docket Number	OMRF 182 DIV	

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		ABAD-ZAPATERO, et al., "Structure of a secreted aspartic protease from <i>C. albicans</i> complexed with a potent inhibitor: implications for the design of antifungal agents," <i>Protein Sci</i> 5(4):640-52 (1996).	
		ABBENATE, et al., "Inhibitors of -amyloid formation based on the -secretase cleavage site," <i>Biochemical and Biophysical Research Communications</i> 268(1):133-135 (2000).	
		ASKEW, et al., "Molecular recognition with convergent functional groups. Synthetic and structural studies with a model receptor for nucleic acid components," <i>J. Am. Chem. Soc.</i> 111, 1082-1090 (1989).	
		BAILEY & COOPER, "A structural comparison of 21 inhibitor complexes of the aspartic proteinase from <i>Endothia parasitica</i>," <i>Protein Sci</i> 3(11):2129-43 (1994).	
		BRUNGER, et al., "Crystallography & NMR system: A new software suite for macromolecular structure determination," <i>Acta Crystallogr D Biol Crystallogr</i> 54 (Pt 5):905-21 (1998).	
		CAPELL, et al., "The proteolytic fragments of the Alzheimer's disease-associated presenilin-1 form heterodimers and occur as a 100-150-kDa molecular mass complex," <i>J Biol Chem</i> 273(6):3205-11 (1998).	
		CHARTIER-HARLIN, et al., "Early-onset Alzheimer's disease caused by mutations at codon 717 of the beta-amyloid precursor protein gene," <i>Nature</i> 353(6347):844-6 (1991).	
		CITRON, et al., "Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production," <i>Nature</i> 360(6405):672-4 (1992).	
		COHEN, et al., "An artificial cell cycle inhibitor isolated from a combinatorial library," <i>Proc Natl Acad Sci USA</i> 95(24):14272-7 (1998).	
		CORDER, et al., "Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families," <i>Science</i> 261(5123):921-3 (1993).	

Examiner's Signature	<i>Abdel A. Mohamed</i>	Date Considered	8/5/03
----------------------	-------------------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	Divisional of 09/603,713
		Filing Date	April 30, 2001
		First Named Inventor	Gerald Koelsch
		Group Art Unit	1653
		Examiner Name	
Sheet 4 of 11	Attorney Docket Number	OMRF 182 DIV	

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		COWLEY, et al., "Alzheimer's unlocking the mystery," <i>Newsweek</i> January 31, 2000.	
		CUTFIELD, et al., "The crystal structure of a major secreted aspartic proteinase from <i>Candida albicans</i> in complexes with two inhibitors," <i>Structure</i> 3(11):1261-71 (1995)	
		DAVIES, "The structure and function of the aspartic proteinases," <i>Annu. Rev. Biophys. Chem.</i> 19:189-215 (1990).	
		DE STROOPER, et al., "Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein," <i>Nature</i> 391(6665):387-90 (1998).	
		DEALWIS, et al., "X-ray analysis at 2.0 Å resolution of mouse submaxillary renin complexed with a decapeptide inhibitor CH-66, based on the 4-16 fragment of rat angiotensinogen," <i>J. Mol. Biol.</i> 236(1):342-60 (1994).	
		DUNN, <i>Structure and Functions of the Aspartic Proteinases</i>, Adv. in Exptl. Med. Biol. 306 (Plenum Press, NY 1991).	
		ELLINGTON & SZOSTAK, "In vitro selection of RNA molecules that bind specific ligands," <i>Nature</i> 346(6287):818-22 (1990).	
		ERMOLIEFF, et al., "Proteolytic activation of recombinant Pro-memapsin 2 (Pro-α-secretase) studied with new fluorogenic substrates," <i>Biochemistry</i> 39(40):12450-12456 (2000)	
		FAN, et al., "BACE Maps to chromosome 11 and a BACE homolog, BACE2, reside in the obligate down syndrome region of chromosome 21," <i>Science</i> 286:1255a (1999)	
		FIELDS & SONG, "A novel genetic system to detect protein-protein interactions," <i>Nature</i> 340(6230):245-6 (1989).	

Examiner's Signature	Abdel A. Mohamed	Date Considered	8/5/03
----------------------	------------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	Divisional of 09/603,713
		Filing Date	April 30, 2001
		First Named Inventor	Gerald Koelsch
		Group Art Unit	1613
		Examiner Name	
Sheet 5 of 11	Attorney Docket Number	OMRF 182 DIV	

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		GHOSH & FIDANZE, Transition-state mimetics for HIV protease inhibitors: Stereocontrolled synthesis of hydroxyethylene and hydroxyethylamine isosteres by ester-derived titanium enolate syn and anti aldol reactions, "Org. Chem. 63:6146-54 (1998).	
		GHOSH, et al., "Design of potent inhibitors for human brain memapsin 2 (-secretase)," J Am Chem Soc 122(14):3522-3523 (2000).	
		GLENNER & WONG, "Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein," Biochem Biophys Res Commun 120(3):885-90 (1984).	
		GOATE, et al., "Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease," Nature 349(6311):704-6 (1991).	
		GOLDGABER, et al., "Characterization and chromosomal localization of a cDNA encoding brain amyloid of Alzheimer's disease," Science 235(4791):877-80 (1987).	
		HAASS & DE STROOPER, "The presenilins in Alzheimer's disease: Proteolysis holds the key," Science 286:916-919 (1999).	
		HONG, et al., "Structure of the protease domain of memapsin 2 (-secretase) complexed with inhibitor," Science 290:150-153 (2000).	
		JAMES, Aspartic Proteinases, Retroviral and Cellular Enzymes, Adv. in Exptl. Med. Biol. 436 (Plenum Press, NY 1998).	
		JONES, et al., "Improved methods for binding protein models in electron density maps and the location of errors in these models" Acta Crystallogr A 47 (Pt 2):110-9 (1991).	
		JORM, ed., A Guide to the Understanding of Alzheimer's Disease and Related Disorders (New York University Press, New York 1987).	

Examiner's Signature	Abdel A. Mohamed	Date Considered	8/5/03
----------------------	------------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	Divisional of 09/603,713
		Filing Date	April 30, 2001
		First Named Inventor	Gerald Koelsch
		Group Art Unit	1653
		Examiner Name	
Sheet 6 of 11	Attorney Docket Number	OMRF 182 DIV	

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		KANG, et al., "The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor," Nature 325(6106):733-6 (1987).	
		KEARNEY & AWEKA, "The penetration of anti-infectives into the central nervous system," Neurol. Clin. 17(4):883-900 (1999).	
		KELLY & DOW, "Microbial differentiation: the role of cellular asymmetry," Microbiol Sci 1(9):214-9 (1984).	
		KHAN, et al., "Lowering the entropic barrier for binding conformationally flexible inhibitors to enzymes," Biochemistry 37(48):16839-45 (1998).	
		KNOPS, et al., "Cell-type and amyloid precursor protein-type specific inhibition of A beta release by bafilomycin A1, a selective inhibitor of vacuolar ATPases," J Biol Chem 270(6):2419-22 (1995).	
		KOLATA, "Scientists find enzyme linked to Alzheimer's," National Science/Health October 22, 1999.	
		KOSTKA, Aspartic proteinases and Their Inhibitor (Walter de Gruyter, Berlin 1985).	
		LASKOWSKI, et al., "Procheck: a program to check the stereochemical quality of protein structures," J Appl. Crystallog 26:283 (1993).	
		LEMAIRE, et al., "The PreA4(695) precursor protein of Alzheimer's disease A4 amyloid is encoded by 16 exons," Nucleic Acids Res 17(2):517-22 (1989).	
		LEVY, et al., "Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch type," Science 248(4959):1124-6 (1990).	

Examiner's Signature	Abdel A. Mohamed	Date Considered	8/5/03
----------------------	------------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	Divisional of 09/603,713
		Filing Date	April 30, 2001
		First Named Inventor	Gerald Koelsch
		Group Art Unit	1653
		Examiner Name	
Sheet 7 of 11	Attorney Docket Number	OMRF 182 DIV	

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		LEVY-LAHAD, et al., "Candidate gene for the chromosome 1 familial Alzheimer's disease locus," <i>Science</i> 269(5226):972-7 (1995).	
		LEWIS & DEAN, "Automated site directed drug design: the concept of spacer skeletons for primary structure generation," <i>Proc R Soc Lond B Biol Sci</i> 236(1283):125-40 and 141-162 (1989).	
		LIN, et al., "Human aspartic protease memapsin 2 cleaves the -secretase site of -amyloid precursor protein," <i>PNAS</i> 97(4):1456-1460 (2000).	
		LIN, et al., "Intracellular diversion of glycoprotein GP160 of human immunodeficiency virus to lysosomes as a strategy of AIDS gene therapy," <i>FASEB J</i> 7(11):1070-80 (1993).	
		MANN, "Cerebral amyloidosis, ageing and Alzheimer's disease; a contribution from studies on Down's syndrome," <i>Neurobiol Aging</i> 10(5):397-9 (1989).	
		MARGINISZYN, et al., "Mode of inhibition of acid proteases by pepstatin," <i>J. Biol. Chem.</i> 251(22):7088-94 (1976).	
		MATSUMOTO, et al., "Molecular cloning of human cDNA with a sequence highly similar to that of the dihydrofolate reductase gene in brain libraries derived from Alzheimer's disease patients," <i>Eur. J. Biochem.</i> 230:337-343 (1995).	
		MCKINLAY & ROSSMANN, "Rational design of antiviral agents," <i>Annu Rev Pharmacol Toxicol</i> 29:111-22 (1989).	
		MECKELEIN, et al., "Identification of a novel serine protease-like molecule in human brain," <i>Molecular Brain Research</i> 55:181-197 (1998).	
		MULLAN, et al., "A locus for familial early-onset Alzheimer's disease on the long arm of chromosome 14, proximal to the alpha 1-antichymotrypsin gene," <i>Nat Genet</i> 2(4):340-2 (1992).	

Examiner's Signature	Abdel A. Mohamed	Date Considered	8/5/03
----------------------	------------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	Divisional of 09/603,713
		Filing Date	April 30, 2001
		First Named Inventor	Gerald Koelsch
		Group Art Unit	1653
		Examiner Name	
Sheet 8 of 11	Attorney Docket Number	OMRF 182 DIV	

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		MULLAN, et al., "A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of beta-amyloid," Nat Genet 4(5):345-7 (1992).	
		MURRELL, et al., "A mutation in the amyloid precursor protein associated with hereditary Alzheimer's disease," Science 254(5028):97-9 (1991).	
		NAVAZA, "AMoRe: an automated package for molecular replacement," Acta Crystallog Sect A 50:157 (1997).	
		OTWINOWSKI & MINOR, "Processing of X-ray diffraction data collected in Oscillation mode," Methods Enzymol 276:307 (1997).	
		PEREZ, et al., "Enhanced release of amyloid beta protein from codon 670/671 "Swedish" mutant beta-amyloid precursor protein occurs in both secretory and endocytic pathways," J Biol Chem 271(15):9100-7 (1996).	
		PERRY & DAVIES, QSAR: Quantitative Structure-Activity Relationships in Drug Design pp. 189-193 (Alan R. Liss, Inc. 1989).	
		PHIMISTER, "Four companies announce discovery of b-secretase gene," Nature Biotechnology 18:16 (2000).	
		PODLISNY, et al., "Presenilin proteins undergo heterogeneous endoproteolysis between Thr291 and Ala299 and occur as stable N- and C-terminal fragments in normal and Alzheimer brain tissue," Neurobiol Dis 3(4):325-37 (1997).	
		RIPKA, "Computers picture the perfect drug," New Scientist 54-57 (1988).	
		ROBAKIS, et al., "Molecular cloning and characterization of a cDNA encoding the cerebrovascular and the neuritic plaque amyloid peptides," Proc Natl Acad Sci U S A 84(12):4190-4 (1987).	

Examiner's Signature	Abdel A. Mohamed	Date Considered	8/5/03
----------------------	------------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	Divisional of 09/603,713
		Filing Date	April 30, 2001
		First Named Inventor	Gerald Koelsch
		Group Art Unit	763
		Examiner Name	
Sheet 9 of 11	Attorney Docket Number	OMRF 182 DIV	

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		ROBERTS & SZOSTAK, "RNA-peptide fusions for the in vitro selection of peptides and proteins," Proc Natl Acad Sci U S A 94(23):12297-302 (1997).	
		ROGAEV, et al., "Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene," Nature 376(6543):776-8 (1996).	
		ROUVINEN, et al., "Computer aided drug design," Acta Pharmaceutica Fennica 97, 159-166 (1996).	
		RUMBLE, et al., "Amyloid A4 protein and its precursor in Down's syndrome and Alzheimer's disease," N Engl J Med 320(22):1446-52 (1989).	
		SEKOE, et al., "Translating cell biology into therapeutic advances in Alzheimer's disease," Nature 399(6738 Suppl):A23-31 (1999).	
		SHERINGTON, et al., "Cloning of a gene bearing missense mutations in early onset familial Alzheimer's disease," Nature 375(6534):754-60 (1996).	
		SINHA & LIEBERBURG, "Cellular mechanisms of beta-amyloid production and secretion," Proc Natl Acad Sci U S A 96(20):11049-53 (1999).	
		SINHA, et al., "Purification and cloning of amyloid precursor protein beta-secretase from human brain," Nature 402(6761):537-40 (1999).	
		STEINER, et al., "Expression of Alzheimer's disease-associated presenilin-1 is controlled by proteolytic degradation and complex formation," J Biol Chem 273(48):32322-31 (1998).	
		SUZUKI, et al., "An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants," Science 264(5163):1336-40 (1994).	

Examiner's Signature	Abdel A. Mohamed	Date Considered	8/5/03
----------------------	------------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	Divisional of 09/603,713		
		Filing Date	April 30, 2001		
		First Named Inventor	Gerald Koelsch		
		Group Art Unit	1653		
		Examiner Name			
Sheet	10	of	11	Attorney Docket Number	OMRF 182 DIV

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		SYMERSKY, et al., "High-resolution structure of the extracellular aspartic proteinase from Candida tropicalis yeast," Biochemistry 36(42):12700-10 (1997).	
		SZOSTAK, "In vitro genetics," TIBS 19:89, (1992).	
		TAGAWA, et al., "Alzheimer's disease amyloid -clipping enzyme (APP secretase): Identification, purification, and characterization of the enzyme," Biochemical and Biophysical Research Communications 177(1):377-387 (1991).	
		TAKAHASHI, Aspartic Proteases, Structure, Function, Biology, Biomedical Implications, Adv. in Exptl. Med. Biol. 362 (Plenum Press, NY 1995).	
		TANG, Acid Proteases, Structure, Function and Biology, Adv. In Exptl. Med. Biol. vol. 95 (Plenum Press, NY 1977).	
		TANG, et al., "Structural evidence for gene duplication in the evolution of the acid proteases," Nature 291(5646):618-21 (1979).	
		TANZI, et al., "Protease inhibitor domain encoded by an amyloid protein precursor mRNA associated with Alzheimer's disease," Nature 331(6156):528-30 (1988).	
		The early story of Alzheimer's Disease, edited by Bick et al. (Raven Press, New York 1987).	
		THINAKARAN, et al., "Endoproteolysis of presenilin 1 and accumulation of processed derivatives in vivo," Neuron 17(1):181-90 (1996).	
		THINAKARAN, et al., "Evidence that levels of presenilins (PS1 and PS2) are coordinately regulated by competition for limiting cellular factors," J Biol Chem 272(45):28415-22 (1997).	

Examiner's Signature	Abdel A. Mohamed	Date Considered	8/5/03
----------------------	------------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	Divisional of 09/603,713		
		Filing Date	April 30, 2001		
		First Named Inventor	Gerald Koelsch		
		Group Art Unit	1653		
		Examiner Name			
Sheet	11	of	11	Attorney Docket Number	OMRF 182 DIV

OTHER ART. -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		THINAKARAN, et al., "Stable association of presenilin derivatives and absence of presenilin interactions with APP," Neurobiol Dis 4(6):438-53 (1998).	
		TURNER, et al., "Substrate specificity of memapsin 2 (secretase), basis for inhibitor drug design for Alzheimer's disease," Experimental Biology 2001 c/o FASEB Office of Scientific Meetings March 31-April 4, 2001, Orlando, Florida. (Abstract)	
		VAN BROECKHOVEN, et al., "Amyloid beta protein precursor gene and hereditary cerebral hemorrhage with amyloidosis (Dutch)," Science 248(4959):1120-2 (1990).	
		VASSAR, et al., "Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE," Science 286(5440):735-41 (1999).	
		WOLFE, et al., "Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity," Nature 398(6727):513-7 (1999).	
		YANG & QUAIL, "Structure of the Rhizomucor miehei aspartic proteinase complexed with the inhibitor pepstatin A at 2.7 Å resolution," Acta Crystallogr D Biol Crystallogr 55 (Pt 3):625-30 (1999).	
		KOSHIKAI, et al., "Genomic organization of the human amyloid beta-protein precursor gene," Gene 87(2):257-63 (1990).	
		YU, "Inhibition of beta-amyloid cytotoxicity by midkine," Neurosci Lett 254(3):125-8 (1998).	

Examiner's Signature	Abdel A. Mohamed	Date Considered	8/5/03
----------------------	------------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO-1449 REPRODUCED		ATTORNEY DOCKET NO. 2932.1008-003 (Formerly OMRP 182 DIV)		APPLICATION NO. 09/845,226	
SUPPLEMENTAL INFORMATION DISCLOSURE CITATION IN AN APPLICATION February 3, 2003 (Use several sheets if necessary)		APPLICANT Gerald Koelsch, et al.			
		FILING DATE April 30, 2001		CONFIRMATION NO. GROUP 4183 FEB 11 2003	
U.S. PATENT DOCUMENTS					
EXAM- INER INI- TIAL		DOCUMENT NUMBER	ISSUE DATE / PUBLICATION DATE		NAME
AM	AA	4,923,967	8 MAY 90		Bobbitt, et al. 350/35
	AB	5,221,607	22 JUNE 93		Cordell et al. 350/399
	AC	5,252,463	12 OCT 93		Nelson et al. 435/251
	AD	5,235,043	10 AUG 93		Collins, et al. 350/399
	AE	5,744,346	28 APR 98		Chrysler, et al. 435/226
	AF	6,291,223 B1	18 SEPT 2001		Christie, et al. 435/212
	AG	6,319,689 B1	20 NOV 2001		Powell, et al. 435/691
	AH	6,361,975 B1	26 MAR 2002		Christie, et al. 435/691
	AI	6,245,884 B1	12 JUN 2001		Hook 350/300
	AJ	6,313,268 B1	06 NOV 2001		Hook 350/350
AM	AK	6,329,163 B1	11 DEC 2001		Anderson, et al. 435/23
FOREIGN PATENT DOCUMENTS					
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS SUB-CLASS TRANSLATION YES NO
AM	AL	WO 02/25276 A1	28 Mar 02	PCT	
AM	AM	WO 01/70672 A2	27 Sept 01	PCT	
AM	AN	0 302 469 A2	8 Feb 89	EPO	
	AO	WO 02/47466 A2	20-JUN-02	PCT	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)					
AM	AR	Ezzell, C., "Alzheimer's Alchemy," Science News 141:152-153 (1992).			
	AS	Majer, P., et al., "Structure-based subsite specificity mapping of human cathepsin D using statine-based inhibitors," Protein Science 6(7): 1458-1466 (1997).			
	AT	Martson, F.A.O. and Hartley, D., "Solubilization of protein aggregates," Methods in Enzymology 182: 264-276 (1990).			
AM	AU	Oefner, C., et al., "Renin inhibition by substituted piperidines: A novel paradigm for the inhibition of monomeric aspartic proteinases?" Chemistry & Biology (London) 6(3): 127-131 (1999).			
EXAMINER		DATE CONSIDERED			
Abdel A. Mohammed		8/5/03			

*PTO-1449 REPRODUCED

 ATTORNEY DOCKET NO.
 2932.1008-003
 (Formerly OMRF 182 DIV)

 APPLICATION NO.
 09/845,226

 SUPPLEMENTAL INFORMATION DISCLOSURE
 CITATION

FEB 10 2003

BY AN APPLICATION

February 3, 2003

Several sheets if necessary)

 APPLICANT
 Gerald Koelsch et al.

 FILING DATE
 April 30, 2001

 CONFIRMATION NO.
 41631653

GROUP

U.S. PATENT DOCUMENTS

EXAM- INER INI- TIAL	DOCUMENT NUMBER	ISSUE DATE / PUBLICATION DATE	NAME
AA3	6,420,534 B1	16 JUL 2002	Gurney et al.
AA2	US 2002/0081634 A1	27 JUN 2002	Gurney, et al.
AC2	US 2002/0055459 A1	09 MAY 2002	Chopra, et al.
AD2	US 2002/0072050 A1	13 JUNE 2002	Hook
AE2	US 2002/0037315 A1	28 MAR 2002	Gurney et al.
AF2	US 2002/0159991 A1	31 OCT 2002	Cordell, et al.
AG2	US 2002/0157122 A1	24 OCT 2002	Wong, et al.
AH2	US 2002/0111365 A1	15 AUG 2002	Wolfe, et al.

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AM	AV	Paris, N., et al., "Bacterial Production and Purification of Recombinant Human Prolactin," <i>Biotech. & Appl. Biochem.</i> 12: 436-449 (1990).
AM	AW	Varon, S., et al., "Neuronotrophic and Neurite-Promoting Factors and Their Clinical Potentials," <i>Dev. Neurosci.</i> 6:73-100 (1983/84).
	AX	Adams, M.D., et al., JP10108681A Cathepsin K Gene Abstract. MicroPatent Bibliographic Database [Online]. [Retrieved on 1999-11-30]. Retrieved from the Internet <URL:http://www.micropat.com/htdocs/com.../nerac.00587727/JP/JP10108681.html>.
	AY	Turner, R.T., et al., "Subsite Specificity of Memapsin 2 (β -Secretase): Implications for Inhibitor Design," <i>Biochem.</i> 40(34):10001-6 (2001).
	AZ	Dorrell, S., "Untangling Alzheimer's disease with β -secretase inhibitors," <i>Drug Discovery Today</i> 5(8):316-317 (2000).
	AR2	Rotello, D.P., "Fenchylamine Sulfonamide Inhibitors of Amyloid β Peptide Production by the γ -Secretase Proteolytic Pathway: Potential Small Molecule Therapeutic Agents for the Treatment of Alzheimer's Disease," <i>Chemtracts-Organic Chemistry</i> 13:626-629 (2000).
	AS2	Howlett, D.R., et al., "In Search of an Enzyme: the β -secretase of Alzheimer's disease is an aspartic proteinase," <i>Trends in Neurosci.</i> 23(11): 565-570 (2000).
	AT2	Ghosh, A.K., et al., "Structure-Based Design: Potent Inhibitors of Human Brain Memapsin 2 (β -Secretase)," <i>J. Med. Chem.</i> , 44:2865-2868 (2001).

EXAMINER

Abdel A. Mohammed

DATE CONSIDERED

8/5/03